109 related articles for article (PubMed ID: 12022686)
1. In vivo pro-apoptotic and antitumor efficacy of a c-Raf antisense phosphorothioate oligonucleotide: relationship to tumor size.
Lau QC; Achenbach TV; Borchers O; Müller R; Slater EP
Antisense Nucleic Acid Drug Dev; 2002 Feb; 12(1):11-20. PubMed ID: 12022686
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative effects of unmodified antisense oligodeoxynucleotides targeted against c-raf mRNA: use of poly (lysine/serine) copolymers or cationic lipopolyamines.
Aoki Y; Kawa S; Karasawa Y; Horiuchi A; Kiyosawa K
Clin Exp Pharmacol Physiol; 1998 Sep; 25(9):702-5. PubMed ID: 9750959
[TBL] [Abstract][Full Text] [Related]
5. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.
Monia BP; Sasmor H; Johnston JF; Freier SM; Lesnik EA; Muller M; Geiger T; Altmann KH; Moser H; Fabbro D
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15481-4. PubMed ID: 8986837
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
Monia BP; Johnston JF; Geiger T; Muller M; Fabbro D
Nat Med; 1996 Jun; 2(6):668-75. PubMed ID: 8640558
[TBL] [Abstract][Full Text] [Related]
8. Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo.
Gokhale PC; McRae D; Monia BP; Bagg A; Rahman A; Dritschilo A; Kasid U
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):191-201. PubMed ID: 10355825
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
Uchida T; Gao JP; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang SX; Kameya T; Baba S
Mol Urol; 2001; 5(2):71-8. PubMed ID: 11690551
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of c-Raf expression induces apoptosis in tumor cells.
Lau QC; Brüsselbach S; Müller R
Oncogene; 1998 Apr; 16(14):1899-902. PubMed ID: 9583688
[TBL] [Abstract][Full Text] [Related]
11. Antisense phosphorothioate oligonucleotides targeted to the human chemokine receptor CXCR4.
Kusunoki A; Miyano-Kurosaki N; Kimura T; Takai K; Yamamoto N; Gushima H; Takaku H
Nucleosides Nucleotides Nucleic Acids; 2000; 19(10-12):1709-19. PubMed ID: 11200267
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells.
Tamura Y; Tao M; Miyano-Kurosaki N; Takai K; Takaku H
Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):87-96. PubMed ID: 10805159
[TBL] [Abstract][Full Text] [Related]
13. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
14. Antisense inhibitory effect: a comparison between 3'-partial and full phosphorothioate antisense oligonucleotides.
Galderisi U; Di Bernardo G; Melone MA; Galano G; Cascino A; Giordano A; Cipollaro M
J Cell Biochem; 1999 Jul; 74(1):31-7. PubMed ID: 10381259
[TBL] [Abstract][Full Text] [Related]
15. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
[TBL] [Abstract][Full Text] [Related]
16. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
18. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
19. Comparison of binding of N3'-->P5' phosphoramidate and phosphorothioate oligonucleotides to cell surface proteins of cultured cells.
Hawley P; Nelson JS; Fearon KL; Zon G; Gibson I
Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):61-9. PubMed ID: 10192290
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
Geiger T; Müller M; Dean NM; Fabbro D
Anticancer Drug Des; 1998 Jan; 13(1):35-45. PubMed ID: 9474241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
